Clostridium difficile infection: Toxins and non-toxin virulence factors, and their contributions to disease establishment and host response

Gut Microbes

Volumn 3, Issue 2, 2012, Pages 121-134

  Vedantam, Gayatri ^a,c   Clark, Andrew ^b   Chu, Michele ^a   McQuade, Rebecca ^a   Mallozzi, Michael ^a   Viswanathan, V K ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTOXUMAB; ADHESIN; BACTERIAL VACCINE; CELL MEMBRANE PROTEIN; CELL SURFACE PROTEIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TRANSFERASE; CLOSTRIDIUM TOXIN; COLLAGEN BINDING PROTEIN; CYSTEINE PROTEASE CWP84; CYSTEINE PROTEINASE; CYTOKINE; FIBRONECTIN BINDING PROTEIN; FIDAXOMICIN; FLAGELLIN; HAPTEN; HEMAGGLUTININ; HEMOLYSIN; MDX 1388; MONOCLONAL ANTIBODY; POLYPEPTIDE ANTIBIOTIC AGENT; POLYSACCHARIDE; POLYSACCHARIDE PS II; SORTASE; THROMBOSPONDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VIRULENCE FACTOR; VON WILLEBRAND FACTOR; BACTERIAL TOXIN;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CELLULAR STRESS RESPONSE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; NITROSYLATION; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RISK FACTOR; SPOROGENESIS; ASIA; BIOLOGICAL MODEL; CLOSTRIDIUM INFECTION; CROSS INFECTION; EUROPE; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; MICROBIOLOGY; NORTH AMERICA; PATHOGENICITY; PATHOLOGY; VIRULENCE;

ANIMALIA; CLOSTRIDIUM DIFFICILE;

ASIA; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; DRUG RESISTANCE, BACTERIAL; EUROPE; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; NORTH AMERICA; VIRULENCE; VIRULENCE FACTORS;

EID: 84866460958     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.19399     Document Type: Review

References (135)

1. Barbut F, Jones G, Eckert C. Epidemiology and control of Clostridium difficile infections in healthcare settings: an update. Curr Opin Infect Dis 2011; 24: 370-376. PMID:21505332. http://dx.doi.org/10.1097/QCO.0b013e32834748e5s
2. Sorg JA, Sonenshein AL. Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J Bacteriol 2009; 191:1115-1117. PMID:19060152. http://dx.doi.org/10.1128/JB.01260-08
3. Viswanathan VK, Mallozzi MJ, Vedantam G. Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes 2010; 1:234-242. PMID:21327030. http://dx.doi.org/10.4161/gmic.1.4.12706
4. Killgore G, Thompson A, Johnson S, Brazier J, Kuijper E, Pepin J, et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsedfield gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandemrepeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J Clin Microbiol 2008; 46:431-437. PMID:18039796. http://dx.doi.org/10.1128/JCM.01484-07
5. Tenover FC, Akerlund T, Gerding DN, Goering RV, Boström T, Jonsson AM, et al. Comparison of strain typing results for Clostridium difficile isolates from North America. J Clin Microbiol 2011; 49:1831-1837. PMID:21389155. http://dx.doi.org/10.1128/JCM.02446-10
6. Stabler RA, Gerding DN, Songer JG, Drudy D, Brazier JS, Trinh HT, et al. Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains. J Bacteriol 2006; 188:7297-305. PMID:17015669. http://dx.doi.org/10.1128/JB.00664-06
7. Dingle KE, Griffiths D, Didelot X, Evans J, Vaughan A, Kachrimanidou M, et al. Clinical Clostridium difficile: clonality and pathogenicity locus diversity. PLoS One 2009; 6:e19993. PMID:21625511. http://dx.doi.org/10.1371/journal.pone.0019993
8. Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, et al. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 2009; 10:R102. PMID:19781061. http://dx.doi.org/10.1186/gb-2009-10-9-r102
9. Brouwer MS, Warburton PJ, Roberts AP, Mullany P, Allan E. Genetic organisation, mobility and predicted functions of genes on integrated, mobile genetic elements in sequenced strains of Clostridium difficile. PLoS One 2011; 6:e23014. PMID:21876735. http://dx.doi.org/10.1371/journal.pone.0023014
10. Valiente E, Dawson LF, Cairns MD, Stabler RA, Wren BW. Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage. J Med Microbiol 2012; 61:49-56. PMID:21903827;http://dx.doi.org/10.1099/jmm.0.036194-0
11. Davies AH, Roberts AK, Shone CC, Acharya KR. Super toxins from a super bug: structure and function of Clostridium difficile toxins. Biochem J 2011; 436: 517-526. PMID:21615333. http://dx.doi.org/10.1042/BJ20110106
12. Soehn F, Wagenknecht-Wiesner A, Leukel P, Kohl M, Weidmann M, von Eichel-Streiber C, et al. Genetic rearrangements in the pathogenicity locus of Clostridium difficile strain 8864-implications for transcription, expression and enzymatic activity of toxins A and B. Mol Gen Genet 1998; 258:222-232. PMID:9645428. http://dx.doi.org/10.1007/s004380050726
13. Ng J, Hirota SA, Gross O, Li Y, Ulke-Lemee A, Potentier MS, et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 2010; 139:542-552, 552, PMID:20398664. http://dx.doi.org/10.1053/j.gastro.2010.04.005
14. Hirota SA, Fines K, Ng J, Traboulsi D, Lee J, Ihara E, et al. Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury. Gastroenterology 2010; 139:259-269, e3. PMID: 20347817. http://dx.doi.org/10.1053/j.gastro.2010.03.045
15. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458:1176-9. PMID:19252482. http://dx.doi.org/10.1038/nature07822
16. Kuehne SA, Cartman ST, Minton NP. Both, toxin A and toxin B, are important in Clostridium difficile infection. Gut Microbes 2011; 2:252-255. PMID: 21804353. http://dx.doi.org/10.4161/gmic.2.4.16109
17. Carter GP, Douce GR, Govind R, Howarth PM, Mackin KE, Spencer J, et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog 2011; 7:e1002317. PMID:22022270;http://dx.doi.org/10.1371/journal.ppat.1002317
18. Sirard S, Valiquette L, Fortier LC. Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. J Clin Microbiol 2011; 49:4040-6. PMID:21956985;http://dx.doi.org/10.1128/JCM.05053-11
19. Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, Johnson S, et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 2010; 192:4904-11. PMID:20675495;http://dx.doi.org/10.1128/JB.00445-10
20. Bacci S, Mølbak K, Kjeldsen MK, Olsen KE. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis 2011; 17:976-982. PMID:21749757. http://dx.doi.org/10.3201/eid1706.101483
21. Schwan C, Stecher B, Tzivelekidis T, van Ham M, Rohde M, Hardt WD, et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog 2009; 5:e1000626. PMID:19834554. http://dx.doi.org/10.1371/journal.ppat.1000626
22. Papatheodorou P, Carette JE, Bell GW, Schwan C, Guttenberg G, Brummelkamp TR, et al. Lipolysisstimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT). Proc Natl Acad Sci U S A 2011; 108:16422-1647. PMID:21930894. http://dx.doi.org/10.1073/pnas.1109772108
23. Kaiser E, Kroll C, Ernst K, Schwan C, Popoff M, Fischer G, et al. Membrane translocation of binary actin-ADP-ribosylating toxins from Clostridium difficile and Clostridium perfringens is facilitated by cyclophilin A and Hsp90. Infect Immun 2011; 79: 3913-3921. PMID:21768281. http://dx.doi.org/10.1128/IAI.05372-11
24. Gerding DN, Muto CA, Owens RC, Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008; 46(Suppl 1):S43-9. PMID: 18177221. http://dx.doi.org/10.1086/521861
25. Merrigan M. Hyper virulent Clostridium difficile strains: Adherence, toxin production and sporulation. Microbiology and Immunology 2010; 178.
26. Akerlund T, Persson I, Unemo M, Norén T, Svenungsson B, Wullt M, et al. Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol 2008; 46:1530-1533. PMID:18287318;http://dx.doi.org/10.1128/JCM.01964-07
27. Burns DA, Heap JT, Minton NP. The diverse sporulation characteristics of Clostridium difficile clinical isolates are not associated with type. Anaerobe 2010; 16:618-622. PMID:20950700. http://dx.doi.org/10.1016/j.anaerobe.2010.10.001
28. Burns DA, Heeg D, Cartman ST, Minton NP. Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027. PLoS One 2011; 6: e24894. PMID:21949780. http://dx.doi.org/10.1371/journal.pone.0024894
29. de Hoon MJ, Eichenberger P, Vitkup D. Hierarchical evolution of the bacterial sporulation network. Curr Biol 2010; 20:R735-R745. PMID:20833318. http://dx.doi.org/10.1016/j.cub.2010.06.031
30. Paredes CJ, Alsaker KV, Papoutsakis ET. A comparative genomic view of clostridial sporulation and physiology. Nat Rev Microbiol 2005; 3:969-978. PMID:16261177. http://dx.doi.org/10.1038/nrmicro1288
31. Harry KH, Zhou R, Kroos L, Melville SB. Sporulation and enterotoxin (CPE) synthesis are controlled by the sporulation-specific sigma factors SigE and SigK in Clostridium perfringens. J Bacteriol 2009; 191:2728-2742;PMID:19201796. http://dx.doi.org/10.1128/JB.01839-08
32. Li J, McClane BA. Evaluating the involvement of alternative sigma factors SigF and SigG in Clostridium perfringens sporulation and enterotoxin synthesis. Infect Immun 2010; 78:4286-4293. PMID:20643850. http://dx.doi.org/10.1128/IAI.00528-10
33. Jones SW, Tracy BP, Gaida SM, Papoutsakis ET. Inactivation of σF in Clostridium acetobutylicum ATCC 824 blocks sporulation prior to asymmetric division and abolishes σE and σG protein expression but does not block solvent formation. J Bacteriol 2011; 193:2429-2440. PMID:21421765. http://dx.doi.org/10.1128/JB.00088-11
34. Saujet L, Monot M, Dupuy B, Soutourina O, Martin-Verstraete I. The key sigma factor of transition phase, SigH, controls sporulation, metabolism, and virulence factor expression in Clostridium difficile. J Bacteriol 2011; 193:3186-3196. PMID:21572003. http://dx.doi.org/10.1128/JB.00272-11
35. Tracy BP, Jones SW, Papoutsakis ET. Inactivation of σE and σG in Clostridium acetobutylicum illuminates their roles in clostridial-cell-form biogenesis, granulose synthesis, solventogenesis, and spore morphogenesis. J Bacteriol 2011; 193:1414-1426. PMID:21217008;http://dx.doi.org/10.1128/JB.01380-10
36. Steiner E, Dago AE, Young DI, Heap JT, Minton NP, Hoch JA, et al. Multiple orphan histidine kinases interact directly with Spo0A to control the initiation of endospore formation in Clostridium acetobutylicum. Mol Microbiol 2011; 80:641-654. PMID:21401736;http://dx.doi.org/10.1111/j.1365-2958.2011.07608.x
37. Underwood S, Guan S, Vijayasubhash V, Baines SD, Graham L, Lewis RJ, et al. Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production. J Bacteriol 2009; 191:7296-7305. PMID:19783633. http://dx.doi.org/10.1128/JB.00882-09
38. Solomon JM, Magnuson R, Srivastava A, Grossman AD. Convergent sensing pathways mediate response to two extracellular competence factors in Bacillus subtilis. Genes Dev 1995; 9:547-558. PMID:7698645. http://dx.doi.org/10.1101/gad.9.5.547
39. Cooksley CM, Davis IJ, Winzer K, Chan WC, Peck MW, Minton NP. Regulation of neurotoxin production and sporulation by a Putative agrBD signaling system in proteolytic Clostridium botulinum. Appl Environ Microbiol 2010; 76:4448-4460. PMID:20453132. http://dx.doi.org/10.1128/AEM.03038-09
40. Li J, Chen J, Vidal JE, McClane BA. The Agr-like quorum-sensing system regulates sporulation and production of enterotoxin and beta2 toxin by Clostridium perfringens type A non-food-borne human gastrointestinal disease strain F5603. Infect Immun 2011; 79:2451-2459. PMID:21464088. http://dx.doi.org/10.1128/IAI.00169-11
41. Setlow P. Spore germination. Curr Opin Microbiol 2003; 6:550-556. PMID:14662349. http://dx.doi.org/10.1016/j.mib.2003.10.001
42. Paredes-Sabja D, Setlow P, Sarker MR. Germination of spores of Bacillales and Clostridiales species: mechanisms and proteins involved. Trends Microbiol 2011; 19:85-94. PMID:21112786. http://dx.doi.org/10.1016/j.tim.2010.10.004
43. Paredes-Sabja D, Setlow P, Sarker MR. GerO, a putative Na+/H+-K+ antiporter, is essential for normal ermination of spores of the pathogenic bacterium Clostridium perfringens. J Bacteriol 2009; 191:3822-3831;PMID:19363115. http://dx.doi.org/10.1128/JB.00158-09
44. Paredes-Sabja D, Setlow P, Sarker MR. SleC is essential for cortex peptidoglycan hydrolysis during germination of spores of the pathogenic bacterium Clostridium perfringens. J Bacteriol 2009; 191:2711-2720. PMID:19218389. http://dx.doi.org/10.1128/JB.01832-08
45. Paredes-Sabja D, Setlow P, Sarker MR. Role of GerKB in germination and outgrowth of Clostridium perfringens spores. Appl Environ Microbiol 2009; 75:3813-3817;PMID:19363077. http://dx.doi.org/10.1128/AEM.00048-09
46. Paredes-Sabja D, Torres JA, Setlow P, Sarker MR. Clostridium perfringens spore germination: characterization of germinants and their receptors. J Bacteriol 2008; 190:1190-11201. PMID:18083820. http://dx.doi.org/10.1128/JB.01748-07
47. Alberto F, Botella L, Carlin F, Nguyen-The C, Broussolle V. The Clostridium botulinum GerAB germination protein is located in the inner membrane of spores. FEMS Microbiol Lett 2005; 253:231-235;PMID:16242862. http://dx.doi.org/10.1016/j.femsle.2005.09.037
48. Burns DA, Heap JT, Minton NP. SleC is essential for germination of Clostridium difficile spores in nutrientrich medium supplemented with the bile salt taurocholate. J Bacteriol 2010; 192:657-664. PMID:19933358. http://dx.doi.org/10.1128/JB.01209-09
49. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 2008; 190:2505-2512. PMID:18245298. http://dx.doi.org/10.1128/JB.01765-07
50. Howerton A, Ramirez N, Abel-Santos E. Mapping interactions between germinants and Clostridium difficile spores. J Bacteriol 2011; 193:274-282. PMID:20971909. http://dx.doi.org/10.1128/JB.00980-10
51. Ramirez N, Liggins M, Abel-Santos E. Kinetic evidence for the presence of putative germination receptors in Clostridium difficile spores. J Bacteriol 2010; 192:4215-4222. PMID:20562307. http://dx.doi.org/10.1128/JB.00488-10
52. Sorg JA, Sonenshein AL. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol 2010; 192:4983-4990. PMID:20675492. http://dx.doi.org/10.1128/JB.00610-10
53. Stecher B, Hardt WD. Mechanisms controlling pathogen colonization of the gut. Curr Opin Microbiol 2011; 14:82-91. PMID:21036098. http://dx.doi.org/10.1016/j.mib.2010.10.003
54. Stecher B, Hardt WD. The role of microbiota in infectious disease. Trends Microbiol 2008; 16:107-114;PMID:18280160. http://dx.doi.org/10.1016/j.tim.2007.12.008
55. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53:994-1002. PMID:22002980;http://dx.doi.org/10.1093/cid/cir632
56. He X, Tian Y, Guo L, Lux R, Zusman DR, Shi W. Oral-derived bacterial flora defends its domain by recognizing and killing intruders-a molecular analysis using Escherichia coli as a model intestinal bacterium. Microb Ecol 2010; 60:655-664. PMID:20625713;http://dx.doi.org/10.1007/s00248-010-9708-4
57. Borriello SP, Barclay FE. An in-vitro model of colonisation resistance to Clostridium difficile infection. J Med Microbiol 1986; 21:299-309. PMID:3723582;http://dx.doi.org/10.1099/00222615-21-4-299
58. McFarland L. Normal flora: diversity and functions. Microb Ecol Health Dis 2000; 12:193-207. http://dx.doi.org/10.1080/08910600050216183
59. Merrigan MM, Sambol SP, Johnson S, Gerding DN. New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents 2009; 33(Suppl 1):S46-S450. PMID:19303570. http://dx.doi.org/10.1016/S0924-8579(09)70017-2
60. Sambol SP, Merrigan MM, Tang JK, Johnson S, Gerding DN. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 2002; 186:1781-1789. PMID:12447764. http://dx.doi.org/10.1086/345676
61. Songer JG, Jones R, Anderson MA, Barbara AJ, Post KW, Trinh HT. Prevention of porcine Clostridium difficile-associated disease by competitive exclusion with nontoxigenic organisms. Vet Microbiol 2007; 124:358-361. PMID:17493774. http://dx.doi.org/10.1016/j.vetmic.2007.04.019
62. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficileassociated diarrhea. J Infect Dis 2008; 197:435-438;PMID:18199029. http://dx.doi.org/10.1086/525047
63. De La Cochetière MF, Durand T, Lalande V, Petit JC, Potel G, Beaugerie L. Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile. Microb Ecol 2008; 56:395-402. PMID:18209965. http://dx.doi.org/10.1007/s00248-007-9356-5
64. Khoruts A, Sadowsky MJ. Therapeutic transplantation of the distal gut microbiota. Mucosal Immunol 2011; 4:4-47. PMID:21150894. http://dx.doi.org/10.1038/mi.2010.79
65. Manges AR, Labbe A, Loo VG, Atherton JK, Behr MA, Masson L, et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis 2010; 202:1877-1884. PMID:21050115;http://dx.doi.org/10.1086/657319
66. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 2011; 108(Suppl 1):4554-4561;PMID:20847294. http://dx.doi.org/10.1073/pnas.1000087107
67. Vengadesan K, Narayana SV. Structural biology of Gram-positive bacterial adhesins. Protein Sci 2011; 20:759-772. PMID:21404359. http://dx.doi.org/10.1002/pro.613
68. Varga JJ, Nguyen V, O'Brien DK, Rodgers K, Walker RA, Melville SB. Type IV pili-dependent gliding motility in the Gram-positive pathogen Clostridium perfringens and other Clostridia. Mol Microbiol 2006; 62:680-694. PMID:16999833. http://dx.doi.org/10.1111/j.1365-2958.2006.05414.x
69. Twine SM, Reid CW, Aubry A, McMullin DR, Fulton KM, Austin J, et al. Motility and flagellar glycosylation in Clostridium difficile. J Bacteriol 2009; 191:7050-7062. PMID:19749038. http://dx.doi.org/10.1128/JB.00861-09
70. Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 2006; 38:779-786;PMID:16804543. http://dx.doi.org/10.1038/ng1830
71. Barketi-Klai A, Hoys S, Lambert-Bordes S, Collignon A, Kansau I. Role of fibronectin-binding protein A in Clostridium difficile intestinal colonization. J Med Microbiol 2011; 60:1155-161. PMID:21349990;http://dx.doi.org/10.1099/jmm.0.029553-0
72. Lin YP, Kuo CJ, Koleci X, McDonough SP, Chang YF. Manganese binds to Clostridium difficile Fbp68 and is essential for fibronectin binding. J Biol Chem 2011; 286:3957-3969. PMID:21062746. http://dx.doi.org/10.1074/jbc.M110.184523
73. Hennequin C, Janoir C, Barc MC, Collignon A, Karjalainen T. Identification and characterization of a fibronectin-binding protein from Clostridium difficile. Microbiology 2003; 149:2779-2787. PMID:14523111;http://dx.doi.org/10.1099/mic.0.26145-0
74. Calabi E, Ward S, Wren B, Paxton T, Panico M, Morris H, et al. Molecular characterization of the surface layer proteins from Clostridium difficile. Mol Microbiol 2001; 40:1187-1199. PMID:11401722. http://dx.doi.org/10.1046/j.1365-2958.2001.02461.x
75. de la Riva L, Willing SE, Tate EW, Fairweather NF. Roles of cysteine proteases Cwp84 and Cwp13 in biogenesis of the cell wall of Clostridium difficile. J Bacteriol 2011; 193:3276-385. PMID:21531808;http://dx.doi.org/10.1128/JB.00248-11
76. Janoir C, Péchiné S, Grosdidier C, Collignon A. Cwp84, a surface-associated protein of Clostridium difficile, is a cysteine protease with degrading activity on extracellular matrix proteins. J Bacteriol 2007; 189:7174-7180. PMID:17693508. http://dx.doi.org/10.1128/JB.00578-07
77. Waligora AJ, Hennequin C, Mullany P, Bourlioux P, Collignon A, Karjalainen T. Characterization of a cell surface protein of Clostridium difficile with adhesive properties. Infect Immun 2001; 69:2144-2153. PMID:11254569. http://dx.doi.org/10.1128/IAI.69.4.2144-2153.2001
78. Reynolds CB, Emerson JE, de la Riva L, Fagan RP, Fairweather NF. The Clostridium difficile cell wall protein CwpV is antigenically variable between strains, but exhibits conserved aggregation-promoting function. PLoS Pathog 2011; 7:e1002024. PMID:21533071;http://dx.doi.org/10.1371/journal.ppat.1002024
79. Calabi E, Calabi F, Phillips AD, Fairweather NF. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect Immun 2002; 70:5770-5778;PMID:12228307. http://dx.doi.org/10.1128/IAI.70.10.5770-5778.2002
80. ChapetónMontes D, Candela T, Collignon A, Janoir C. Localization of the Clostridium difficile cysteine protease Cwp84 and insights into its maturation process. J Bacteriol 2011; 193:5314-5321. PMID:21784932. http://dx.doi.org/10.1128/JB.00326-11
81. Fagan RP, Janoir C, Collignon A, Mastrantonio P, Poxton IR, Fairweather NF. A proposed nomenclature for cell wall proteins of Clostridium difficile. J Med Microbiol 2011; 60:1225-1228. PMID:21252271. http://dx.doi.org/10.1099/jmm.0.028472-0
82. Fagan RP, Albesa-Jové D, Qazi O, Svergun DI, Brown KA, Fairweather NF. Structural insights into the molecular organization of the S-layer from Clostridium difficile. Mol Microbiol 2009; 71:1308-1322. PMID:19183279. http://dx.doi.org/10.1111/j.1365-2958.2009.06603.x
83. Karjalainen T, Waligora-Dupriet AJ, Cerquetti M, Spigaglia P, Maggioni A, Mauri P, et al. Molecular and genomic analysis of genes encoding surface-anchored proteins from Clostridium difficile. Infect Immun 2001; 69:3442-3446. PMID:11292772. http://dx.doi.org/10.1128/IAI.69.5.3442-3446.2001
84. Swidsinski A, Sydora BC, Doerffel Y, Loening-Baucke V, Vaneechoutte M, Lupicki M, et al. Viscosity gradient within the mucus layer determines the mucosal barrier function and the spatial organization of the intestinal microbiota. Inflamm Bowel Dis 2007; 13:963-970. PMID:17455202. http://dx.doi.org/10.1002/ibd.20163
85. Swidsinski A, Loening-Baucke V, Theissig F, Engelhardt H, Bengmark S, Koch S, et al. Comparative study of the intestinal mucus barrier in normal and inflamed colon. Gut 2007; 56:343-350. PMID:16908512. http://dx.doi.org/10.1136/gut.2006.098160
86. O'Neil HS, Marquis H. Listeria monocytogenes flagella are used for motility, not as adhesins, to increase host cell invasion. Infect Immun 2006; 74:6675-81. PMID:16982842. http://dx.doi.org/10.1128/IAI.00886-06
87. Crawford RW, Reeve KE, Gunn JS. Flagellated but not hyperfimbriated Salmonella enterica serovar Typhimurium attaches to and forms biofilms on cholesterol-coated surfaces. J Bacteriol 2010; 192: 2981-2990. PMID:20118264. http://dx.doi.org/10.1128/JB.01620-0988.
88. Stecher B, Hapfelmeier S, Müller C, Kremer M, Stallmach T, Hardt WD. Flagella and chemotaxis are required for efficient induction of Salmonella enterica serovar Typhimurium colitis in streptomycinpretreated mice. Infect Immun 2004; 72:4138-4150.PMID:15213159. http://dx.doi.org/10.1128/IAI.72.7.4138-4150.2004
89. Erdem AL, Avelino F, Xicohtencatl-Cortes J, Girón JA. Host protein binding and adhesive properties of H6 and H7 flagella of attaching and effacing Escherichia coli. J Bacteriol 2007; 189:7426-7435.PMID:17693516. http://dx.doi.org/10.1128/JB.00464-07
90. Pituch H, Obuch-Woszczatyñski P, van den Braak N, van Belkum A, Kujawa M, Luczak M, et al. Variable flagella expression among clonal toxin A-/B+Clostridium difficile strains with highly homogeneous flagellin genes. Clin Microbiol Infect 2002; 8:187-188.PMID:12010175;http://dx.doi.org/10.1046/j.1469-0691.2002.00394.x
91. Delmée M, Avesani V, Delferriere N, Burtonboy G. Characterization of flagella of Clostridium difficile and their role in serogrouping reactions. J Clin Microbiol 1990; 28:2210-2214.PMID:2229343
92. Martirosian G, Wize J, Sokół-Leszczyńska B, Zielińska U, Meisel-Mikołajczyk F, Maśliński S. Comparison of Delme ́e and Polish serogroup-specific Clostridium difficile strains. Acta Microbiol Pol 1993; 42:251-257.PMID:7516616
93. Tasteyre A, Barc MC, Collignon A, Boureau H, Karjalainen T. Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect Immun 2001; 69:7937-7940.PMID:11705981;http://dx.doi.org/10.1128/IAI.69.12.7937-7940.2001
94. Tasteyre A, Karjalainen T, Avesani V, Delmée M, Collignon A, Bourlioux P, et al. Phenotypic and genotypic diversity of the flagellin gene (fliC) among Clostridium difficile isolates from different serogroups. J Clin Microbiol 2000; 38:3179-3186.PMID:10970353
95. Tasteyre A, Barc MC, Karjalainen T, Dodson P, Hyde S, Bourlioux P, et al. A Clostridium difficile gene encoding flagellin. Microbiology 2000; 146:957-966.PMID:10784054
96. Arora SK, Ritchings BW, Almira EC, Lory S, Ramphal R. The Pseudomonas aeruginosa flagellar cap protein, FliD, is responsible for mucin adhesion. Infect Immun 1998; 66:1000-1007.PMID:9488388
97. Tasteyre A, Karjalainen T, Avesani V, Delmée M, Collignon A, Bourlioux P, et al. Molecular characterization of fliD gene encoding flagellar cap and its expression among Clostridium difficile isolates from different serogroups. J Clin Microbiol 2001; 39:1178-183.PMID:11230454. http://dx.doi.org/10.1128/JCM.39.3.1178-1183.2001
98. Guerry P, Ewing CP, Schirm M, Lorenzo M, Kelly J, Pattarini D, et al. Changes in flagellin glycosylation affect Campylobacter autoagglutination and virulence. Mol Microbiol 2006; 60:299-311.PMID:16573682. http://dx.doi.org/10.1111/j.1365-2958.2006.05100.x
99. Canals R, Ramirez S, Vilches S, Horsburgh G, Shaw JG, Tomás JM, et al. Polar flagellum biogenesis in Aeromonas hydrophila. J Bacteriol 2006; 188:542-555; PMID:16385045. http://dx.doi.org/10.1128/JB.188.2.542-555.2006
100. Dingle TC, Mulvey GL, Armstrong GD. Mutagenic analysis of the Clostridium difficile flagellar proteins, FliC and FliD, and their contribution to virulence in hamsters. Infect Immun 2011; 79:4061-4067.PMID: 21788384. http://dx.doi.org/10.1128/IAI.05305-11
101. Marsden GL, Davis IJ, Wright VJ, Sebaihia M, Kuijper EJ, Minton NP. Array comparative hybridisation reveals a high degree of similarity between UK and European clinical isolates of hypervirulent Clostridium difficile. BMC Genomics 2010; 11:389.PMID:20565959;http://dx.doi.org/10.1186/1471-2164-11-389
102. Martin CE, Weishaupt MW, Seeberger PH. Progress toward developing a carbohydrate-conjugate vaccine against Clostridium difficile ribotype 027: synthesis of the cell-surface polysaccharide PS-I repeating unit. Chem Commun (Camb) 2011; 47:10260-10262.PMID:21998885. http://dx.doi.org/10.1039/c1cc13614c
103. Danieli E, Lay L, Proietti D, Berti F, Costantino P, Adamo R. First synthesis of C. difficile PS-II cell wall polysaccharide repeating unit. Org Lett 2011; 13:378-381.PMID:21190352. http://dx.doi.org/10.1021/ol1026188
104. Ganeshapillai J, Vinogradov E, Rousseau J, Weese JS, Monteiro MA. Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units. Carbohydr Res 2008; 343:703-710.PMID:18237724. http://dx.doi.org/10.1016/j.carres.2008.01.002
105. Weidenmaier C, Peschel A. Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions. Nat Rev Microbiol 2008; 6: 276-287.PMID:18327271. http://dx.doi.org/10.1038/nrmicro1861
106. Weidenmaier C, Kokai-Kun JF, Kulauzovic E, Kohler T, Thumm G, Stoll H, et al. Differential roles of sortase-anchored surface proteins and wall teichoic acid in Staphylococcus aureus nasal colonization. Int J Med Microbiol 2008; 298:505-13.PMID:18221914;http://dx.doi.org/10.1016/j.ijmm.2007.11.006
107. Vollmer W. Structural variation in the glycan strands of bacterial peptidoglycan. FEMS Microbiol Rev 2008; 32:287-306.PMID:18070068. http://dx.doi.org/10.1111/j.1574-6976.2007.00088.x
108. Ho TD, Ellermeier CD. PrsW is required for colonization, resistance to antimicrobial peptides, and expression of extracytoplasmic function s factors in Clostridium difficile. Infect Immun 2011; 79:3229-3238.PMID:21628514. http://dx.doi.org/10.1128/IAI.00019-11
109. Peltier J, Courtin P, El Meouche I, Lemée L, Chapot- Chartier MP, Pons JL. Clostridium difficile has an original peptidoglycan structure with a high level of N-acetylglucosamine deacetylation and mainly 3-3 cross-links. J Biol Chem 2011; 286:29053-29062.PMID:21685382. http://dx.doi.org/10.1074/jbc.M111.259150
110. Boneca IG, Dussurget O, Cabanes D, Nahori MA, Sousa S, Lecuit M, et al. A critical role for peptidoglycan N-deacetylation in Listeria evasion from the host innate immune system. Proc Natl Acad Sci U S A 2007; 104:997-1002.PMID:17215377. http://dx.doi.org/10.1073/pnas.0609672104
111. Vollmer W, Tomasz A. Peptidoglycan N-acetylglucosamine deacetylase, a putative virulence factor in Streptococcus pneumoniae. Infect Immun 2002; 70: 7176-7178.PMID:12438406. http://dx.doi.org/10.1128/IAI.70.12.7176-7178.2002
112. Drudy D, Calabi E, Kyne L, Sougioultzis S, Kelly E, Fairweather N, et al. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol 2004; 41:237-242, 42;PMID:15196573. http://dx.doi.org/10.1016/j.femsim.2004.03.007
113. Bianco M, Fedele G, Quattrini A, Spigaglia P, Barbanti F, Mastrantonio P, et al. Immunomodulatory activities of surface-layer proteins obtained from epidemic and hypervirulent Clostridium difficile strains. J Med Microbiol 2011; 60:1162-1167.PMID:21349985. http://dx.doi.org/10.1099/jmm.0.029694-0
114. Takeuchi O, Akira S. Toll-like receptors; theirphysiological role and signal transduction system. Int Immunopharmacol 2001; 1:625-635.PMID:11357875;http://dx.doi.org/10.1016/S1567-5769(01)00010-8
115. Ryan A, Lynch M, Smith SM, Amu S, Nel HJ, McCoy CE, et al. A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog 2011; 7:e1002076.PMID: 21738466. http://dx.doi.org/10.1371/journal.ppat.1002076
116. Jarchum I, Liu M, Lipuma L, Pamer EG. Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect Immun 2011;79:1498-1503.PMID:21245274. http://dx.doi.org/10.1128/IAI.01196-10
117. McBride SM, Sonenshein AL. The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile. Microbiology 2011; 157:1457-1465.PMID:21330441. http://dx.doi.org/10.1099/mic.0.045997-0
118. McBride SM, Sonenshein AL. Identification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficile. Infect Immun 2011; 79:167-176.PMID:20974818. http://dx.doi.org/10.1128/IAI.00731-10
119. Sibartie S, O'Hara AM, Ryan J, Fanning A, O'Mahony J, O'Neill S, et al. Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria. BMC Immunol 2009; 10:54.PMID:19814810;http://dx.doi.org/10.1186/1471-2172-10-54
120. Johnson S, Gerding DN, Janoff EN. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis 1992;166:1287-1294.PMID:1431247. http://dx.doi.org/10.1093/infdis/166.6.1287
121. Aronsson B, Granström M, Möllby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985; 13:97-101.PMID:4030111. http://dx.doi.org/10.1007/BF01642866
122. Savidge TC, Urvil P, Oezguen N, Ali K, Choudhury A, Acharya V, et al. Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. Nat Med 2011; 17:1136-1141.PMID:21857653. http://dx.doi.org/10.1038/nm.2405
123. Qiu B, Pothoulakis C, Castagliuolo I, Nikulasson Z, LaMont JT. Nitric oxide inhibits rat intestinal secretion by Clostridium difficile toxin A but not Vibrio cholerae enterotoxin. Gastroenterology 1996; 111:409-418.PMID:8690206. http://dx.doi.org/10.1053/gast.1996.v111.pm8690206
124. Sandolo C, Péchiné S, Le Monnier A, Hoys S, Janoir C, Coviello T, et al. Encapsulation of Cwp84 into pectin beads for oral vaccination against Clostridium difficile. Eur J Pharm Biopharm 2011; 79:566-573;PMID:21664462. http://dx.doi.org/10.1016/j.ejpb.2011.05.011
125. Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J, Fairweather NF, et al. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun 2011; 79:2295-22302.PMID:21482682. http://dx.doi.org/10.1128/IAI.00130-11
126. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010; 28:965-969.PMID:19941990. http://dx.doi.org/10.1016/j.vaccine.2009.10.144
127. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205.PMID:20089970. http://dx.doi.org/10.1056/NEJMoa0907635
128. Péchiné S, Denève C, Le Monnier A, Hoys S, Janoir C, Collignon A. Immunization of hamsters against Clostridium difficile infection using the Cwp84 protease as an antigen. FEMS Immunol Med Microbiol 2011; 63:73-81.PMID:21707776. http://dx.doi.org/10.1111/j.1574-695X.2011.00832.x
129. Oberli MA, Hecht ML, Bindschädler P, Adibekian A, Adam T, Seeberger PH. A possible oligosaccharideconjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem Biol 2011; 18:580-588.PMID:21609839. http://dx.doi.org/10.1016/j.chembiol.2011.03.009
130. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9:1044-1049.PMID:21871249. http://dx.doi.org/10.1016/j.cgh.2011.08.014
131. Landy J, Al-Hassi HO, McLaughlin SD, Walker AW, Ciclitira PJ, Nicholls RJ, et al. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011; 34:409-415.PMID:21682755. http://dx.doi.org/10.1111/j.1365-2036.2011.04737.x
132. Mullane KM, Gorbach S. Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther 2011; 9:767-777.PMID:21810048. http://dx.doi.org/10.1586/eri.11.53
133. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-431.PMID:21288078. http://dx.doi.org/10.1056/NEJMoa0910812
134. Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010; 156:3354-359.PMID:20724385. http://dx.doi.org/10.1099/mic.0.042010-0
135. Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in ndividuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53:440-447;PMID:21844027. http://dx.doi.org/10.1093/cid/cir404